People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...

to reduce their blood glucose levels glucagon-like peptide-1 (GLP-1) receptor agonists — these stimulate insulin secretion, inhibit the production of glucagon and slow down stomach emptying; they have ...

Neurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...